Update: On September 1, 2020, BRDD revised its Report to correct the “Biosimilars: Market Authorizations” tables.
The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD; formerly BGTD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for Fiscal Year 2019-2020. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical, and non-prescription and disinfectant drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2015-2016 to 2019-2020.
Related Publications & Articles
-
Update on proposed Ministerial Reliance Order
As we reported last month, the Minister of Health launched a consultation on a proposed Ministerial Reliance Order that would permit Health Canada to complete the examination of certain parts of a dru...Read More -
Canada announces new Pharmaceutical and Life Sciences Sector Task Force
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and ...Read More -
Regulatory and IP considerations for veterinary drugs in Canada
This article provides an overview of the regulatory regime and associated intellectual property rights for veterinary drug products and provides an update on recent issues, focusing on features that d...Read More
